, Volume 41, Issue 2, pp 193–201 | Cite as

Osteoarthritis 1991

Current Drug Treatment Regimens
  • Abdulrhman Al Arfag
  • Paul Davis
Practical Therapeutic


Osteoarthritis, the most common rheumatic disease, presents the clinician with a major therapeutic and management task. The chronic and progressive course of the disease is punctuated by pain, declining function and escalating disability. This article attempts to deal with the pharmacological therapeutic options available to us in the management of osteoarthritis. Other non-pharmacological therapeutic modalities are also briefly discussed, including patient education, joint protection, physiotherapy, occupational therapy and surgery. Drug therapy as discussed focuses on the control of pain and inflammation.

For this intermittently painful condition analgesic drugs assume a very important role. Non-steroidal anti-inflammatory drugs (NSAIDs) have combined analgesic and anti-inflammatory properties which are particularly useful in many patients who manifest inflammation in addition to pain. While systemic steroids have no role in the treatment of osteoarthritis, intra-articular steroid injections may be of benefit. In trying to slow the degenerative process chondroprotective agents such as glycosaminoglycan may also assume increasing importance in the future. Choosing one drug over another must be done after consideration of many factors including the therapeutic and toxicity profile of the drugs involved, their pharmacology and dose regimen, the patient profile, cost and the desired effect.


Osteoarthritis Piroxicam Sulindac Tiaprofenic Acid Fenoprofen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agrawal NM, Dajani EZ. Options in the treatment and prevention of NSAID-induced gastro-duodenal mucosal damage. Journal of Rheumatology 17 (Suppl. 20): 7–11, 1990Google Scholar
  2. Behrens F, Shepard N, Mitchell N. Metabolic recovery of articular cartilage after intra-articular injection of glucocorticords. Journal of Bone and Joint Surgery 58A: 1157–1160, 1976Google Scholar
  3. Bennett WM, Debroe ME. Analgesic nephropathy: a preventable renal disease. New England Journal of Medicine 320(19): 1269–1271, 1989PubMedCrossRefGoogle Scholar
  4. Burkhardt D, Ghosh P. Laboratory evaluation of anti arthritic drugs as potential chondroprotective agents. Seminars in Arthritis and Rheumatism 17 (Suppl. 1): 3–34, 1987PubMedGoogle Scholar
  5. Calin A, Cawley B, Pal JN, et al. Multicentre double-blind comparison of sustained action formulations of tiaprofenic acid and indomethacin in osteoarthritis. Drugs 35 (Suppl. 1): 57–63, 1988PubMedCrossRefGoogle Scholar
  6. Ciabattoni G, Cinotti GA, Pierucci A, et al. Effects of sulindac and ibuprofen in patients with chronic glomerular disease and evidence for the dependence of renal function on prostacyclin. New England Journal of Medicine 310: 279, 1984PubMedCrossRefGoogle Scholar
  7. Colombo C, Butler M, Hickman L, et al. A new model of osteoarthritis in rabbits. III. Evaluation of antiarthrosic effects of selected drugs administered intraarticularly. Arthritis and Rheumatism 26: 1132–1139, 1983PubMedCrossRefGoogle Scholar
  8. Davis P. Therapeutic options in the selection of nonsteroidal antiinflammatory drugs in the treatment of osteoarthritis: a review. Journal of Rheumatology 14 (Suppl. 14): 94–97, 1987PubMedGoogle Scholar
  9. DiPadova C. S-Adenosylmethionine in the treatment of osteoarthritis. American Journal of Medicine 83 (Suppl. 5A): 60–64, 1987CrossRefGoogle Scholar
  10. Doherty M, Dieppe PA. Effect of intraarticular Yttrium 90 (90Y) on chronic pyrophosphate arthropathy (CPA) of the knee. Annals of the Rheumatic Diseases 40: 626, 1981CrossRefGoogle Scholar
  11. Doyle DV, Dieppe PA, Scott J, Huskisson EC. An articular index for the assessment of osteoarthritis. Annals of the Rheumatic Diseases 40: 75–78, 1981PubMedCrossRefGoogle Scholar
  12. Ehrlich GE. Future directions in therapy of pain in osteoarthritis. Seminars in Arthritis and Rheumatism 18 (Suppl. 2): 100–104, 1989PubMedCrossRefGoogle Scholar
  13. Frankhof W. Controlled-release naproxen compared with isoxicam in patients with osteoarthritis. Current Medical Research and Opinion 11(1): 28–33, 1988PubMedCrossRefGoogle Scholar
  14. Fuji K, Tajiri K, Kajiwara T, Tanaka T, Murota K. Effects of NSAID on collagen and proteoglycan synthesis of cultured chondrocytes. Journal of Rheumatology 16 (Suppl. 18): 28–31, 1989Google Scholar
  15. Gatter RA. Arthrocentesis technique anmd intrasynovial therapy. In McCarty DJ (Ed.) Arthritis and allied conditions, 11th ed., pp. 646–656, Lea & Febiger, Philadelphia, 1989Google Scholar
  16. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 2: 1277–1280, 1988PubMedCrossRefGoogle Scholar
  17. Hoaglund FT, Yau ACMC, Wong WL. Osteoarthritis of the hip and other joints in Southern Chinese in Hong Kong. Journal of Bone and Joint Surgery 55A: 645–657, 1973Google Scholar
  18. Howell DS, Carreno MR, Pelletier J-P. Articular cartilage breakdown in a lapine model of osteoarthritis. Clinical Orthopaedics and Related Research 213: 69–76, 1986PubMedGoogle Scholar
  19. Hurkisson EC, Doyle DV, Lanhan JG. Drug treatment of osteoarthritis. Clinics in Rheumatic Diseases — Osteoarthritis. 2(2): 421–431, 1985Google Scholar
  20. Jaffe JH, Martin WR. The pharmacological basis of therapeutics, 7th ed., pp. 491–581, MacMillan Publishing Company, 1985Google Scholar
  21. Kantor TG. Concepts in pain control. Seminars in Arthritis and Rheumatism 18 (Suppl. 2): 94–99, 1989PubMedCrossRefGoogle Scholar
  22. Maccagno A, Sabastian O, Di Giorgioe E. Comparative double-blind study of tiaprofenic acid versus piroxieam in the treatment of osteoarthritis of the knee. Drugs 35 (Suppl. 1): 64–67, 1988PubMedCrossRefGoogle Scholar
  23. Mankin HJ. Kelley’s textbook of rheumatology. 3rd ed., pp. 1480–1510, W.B. Saunders, 1989Google Scholar
  24. Mankin HJ, Conger KA. Acute effects of intra-articular hyflrocortisone on articular cartilage in rabbits. Journal of Bone and Joint Surgery 48A: 1383–1388s 1986Google Scholar
  25. McCarty DJ. Treatment of rheumatoid joint inflammation with triamcinolone hexacetonide. Arthritis and Rheumatism 15: 157–173, 1972PubMedCrossRefGoogle Scholar
  26. Moskowitz RW, Brandt KD. In McCarty DJ (Ed.) Arthritis and allied conditions, 11th ed., pp. 1605–1641, Lea & Febiger,1989Google Scholar
  27. Moskowitz RW, et al. Experimentally induced corticosteroid arthropathy. Arthritis and Rheumatism 13: 236–243, 1970PubMedCrossRefGoogle Scholar
  28. Moskowitz RW, Goldberg V, Schwab W. Effects of intra articular cortico-steroids and exercise in experimental models of inflammatory and degenerative arthritis. Arthritis and Rheumatism 18: 417, 1975Google Scholar
  29. Mukhopadhaya B, Baroodh B. Osteoarthritis of hip in Indians: an anatomical and clinical study. Indian Journal of Orthopaedics 1: 55–62, 1967Google Scholar
  30. Neustadt DH. Intra-articular therapy for rheumatoid synovitis of the knee: effect of the post injection rest regimen. Clinical Rheumatology in Practice 3: 65–68, 1985Google Scholar
  31. Neustadt DH. Intra-articular therapy. In Schumacher HR et al. (Eds) Primer on rheumatic diseases, 9th ed., pp. 294–296, Arthritis Foundation, Atlanta GA, 1989Google Scholar
  32. Paulus H. In Schumacher HR et al. (Eds) Primer on rheumatic diseases, 9th ed., pp. 282–288, Arthritis Foundation, Atlanta GA, 1989Google Scholar
  33. Pelletier JP, Martel-Pelletier J. Evidence for the involvement of interleukin 1 in human osteoarthritic cartilage degradation: protective effect of NSAID. Journal of Rheumatology 16 (Suppl. 18): 16–27, 1989Google Scholar
  34. Rejholec V. Long term studies of anti osteoarthritic drugs: an assessment. Seminars in Arthritis and Rheumatism 17 (Suppl. 11): 35–53, 1987PubMedGoogle Scholar
  35. Roughley PJ. Structural changes in the proteoglycan of human articular cartilage during aging. Journal of Rheumatology 14 (Suppl. 14): 14–15, 1987PubMedGoogle Scholar
  36. Sandier DP, Smith JC, Weinberg CR, Buckalew Jr VM. Analgesic use and chronic renal disease. New England Journal of Medicine 320(19): 1238, 1989CrossRefGoogle Scholar
  37. Sokoloff L. Osteoarthritis as a remodelling process. Journal of Rheumatology 14 (Suppl. 14): 7–10, 1987PubMedGoogle Scholar
  38. Waisen TA, McCauley FA, Wilson TW. Sulindac does not spare renal prostaglandins. Clinical and Investigative Medicine 12(2): 77–81, 1989Google Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Abdulrhman Al Arfag
    • 1
  • Paul Davis
    • 1
  1. 1.562 Heritage Medical Research CentreUniversity of AlbertaEdmontonCanada

Personalised recommendations